Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,017 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. Among authors: emery s. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
Reply.
Emery S, Lane HC, Neaton JD. Emery S, et al. J Infect Dis. 2000 Jan;183(4):680. doi: 10.1086/318546. J Infect Dis. 2000. PMID: 11171000 No abstract available.
Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
French M, Amin J, Roth N, Carr A, Law M, Emery S, Drummond F, Cooper D; OzCombo 2 investigators. French M, et al. Among authors: emery s. HIV Clin Trials. 2002 May-Jun;3(3):177-85. doi: 10.1310/9n21-1hg1-7n1q-jkw1. HIV Clin Trials. 2002. PMID: 12032876 Clinical Trial.
A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals.
Pett SL, Williams LA, Day RO, Lloyd AR, Carr AD, Clezy KR, Emery S, Kaplan E, McPhee DA, McLachlan AJ, Gelder FB, Lewin SR, Liauw W, Williams KM. Pett SL, et al. Among authors: emery s. HIV Clin Trials. 2004 Mar-Apr;5(2):91-8. doi: 10.1310/1FLN-8KFC-5HEQ-K19J. HIV Clin Trials. 2004. PMID: 15116285 Clinical Trial.
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Ungsedhapand C, Srasuebkul P, Cardiello P, Ruxrungtham K, Ratanasuwan W, Kroon ED, Tongtalung M, Juengprasert N, Ubolyam S, Siangphoe U, Emery S, Lange JM, Cooper DA, Phanuphak P; HIV-NAT 002 and HIV-NAT 003 Study Team. Ungsedhapand C, et al. Among authors: emery s. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):693-701. doi: 10.1097/00126334-200406010-00006. J Acquir Immune Defic Syndr. 2004. PMID: 15167288 Clinical Trial.
1,017 results